HC Wainwright Forecasts Perspective Therapeutics Q2 Earnings

Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) – Equities research analysts at HC Wainwright increased their Q2 2026 earnings per share (EPS) estimates for Perspective Therapeutics in a research note issued on Monday, June 1st. HC Wainwright analyst R. Burns now forecasts that the company will post earnings of ($0.23) per share for the quarter, up from their previous estimate of ($0.25). HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for Perspective Therapeutics’ current full-year earnings is ($1.14) per share. HC Wainwright also issued estimates for Perspective Therapeutics’ Q3 2026 earnings at ($0.23) EPS, Q4 2026 earnings at ($0.24) EPS and FY2026 earnings at ($0.96) EPS.

A number of other equities analysts have also recently issued reports on the company. Truist Financial set a $12.00 target price on Perspective Therapeutics in a report on Tuesday, March 17th. UBS Group lifted their target price on Perspective Therapeutics from $7.00 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, March 18th. Piper Sandler started coverage on Perspective Therapeutics in a research report on Thursday, February 19th. They set an “overweight” rating and a $16.00 price target for the company. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a report on Tuesday, May 5th. Finally, Royal Bank Of Canada cut their price objective on shares of Perspective Therapeutics from $18.00 to $14.00 and set an “outperform” rating on the stock in a research report on Tuesday, March 17th. One analyst has rated the stock with a Strong Buy rating and eight have issued a Buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics has a consensus rating of “Buy” and an average target price of $12.63.

Perspective Therapeutics Stock Performance

Shares of NYSEAMERICAN:CATX opened at $3.60 on Wednesday. Perspective Therapeutics has a 12 month low of $1.96 and a 12 month high of $6.16. The company’s fifty day simple moving average is $4.13 and its 200 day simple moving average is $3.72.

Perspective Therapeutics (NYSEAMERICAN:CATX) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.29) by $0.04. The company had revenue of $0.08 million during the quarter, compared to the consensus estimate of $0.16 million. Perspective Therapeutics had a negative return on equity of 42.33% and a negative net margin of 17,982.69%.

Hedge Funds Weigh In On Perspective Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Russell Investments Group Ltd. lifted its stake in Perspective Therapeutics by 184.1% in the third quarter. Russell Investments Group Ltd. now owns 8,449 shares of the company’s stock valued at $29,000 after acquiring an additional 5,475 shares during the last quarter. Aigen Investment Management LP bought a new position in Perspective Therapeutics during the fourth quarter worth about $28,000. nVerses Capital LLC acquired a new position in Perspective Therapeutics during the fourth quarter worth approximately $31,000. Abel Hall LLC bought a new stake in Perspective Therapeutics in the first quarter valued at approximately $49,000. Finally, Engineers Gate Manager LP acquired a new stake in shares of Perspective Therapeutics in the fourth quarter valued at approximately $35,000. 54.66% of the stock is owned by institutional investors.

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.